Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Current Search

Report Type

Organization

Disposition

Year

Month

Found 6587 record(s)

Req # A-2024-001126

Adverse Drug Reactions (ADRs). Report numbers: 001113056, 001115140, 001117655, 001117861, 001118555, 001119089, 001124617.

Organization: Health Canada

28 page(s)
January 2025

Req # A-2024-001127

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 24-108016-770, Deputy Ministerial Meeting with the Food and Biologics Laboratories.

Organization: Health Canada

6 page(s)
January 2025

Req # A-2024-001128

Adverse Drug Reaction (ADR). Report number: 001105313.

Organization: Health Canada

3 page(s)
January 2025

Req # A-2024-001129

Adverse Drug Reactions (ADRs) for Leuprorelin. Report numbers: E2B_07277786, E2B_07277588, E2B_07305771, E2B_07188397, E2B_07280528, E2B_06647559, E2B_06733896, E2B_06067651, E2B_07288711, E2B_07035040.

Organization: Health Canada

75 page(s)
January 2025

Req # A-2024-001132

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 24-108304-762, Deputy Ministerial Attendance at Event: Public Policy Forum's Fall Lecture 2024: Canada’s Relationship with the United States.

Organization: Health Canada

9 page(s)
January 2025

Req # A-2024-001143

Adverse Drug Reactions (ADRs) for Leuprorelin. Report numbers: E2B_07260682, E2B_07302196, E2B_07289202, E2B_07277761, E2B_07232658, E2B_07302815, E2B_07277745, E2B_07374906, E2B_07372301, E2B_07357402.

Organization: Health Canada

102 page(s)
January 2025

Req # A-2024-001145

Adverse Drug Reactions (ADRs) for Leuprorelin. Report numbers: E2B_07320794, 001083465, E2B_07371958, E2B_07337706, E2B_07374805, E2B_07378579, E2B_07386026, E2B_07372301, E2B_07391385, 001114870.

Organization: Health Canada

84 page(s)
January 2025

Req # A-2024-001146

Adverse Drug Reactions (ADRs) for Leuprorelin. Report numbers: E2B_07383501, E2B_07357402, E2B_07415375, E2B_07414754, E2B_07405718, E2B_07405746. ADRs for Leuprolide. Report numbers: E2B_07286169, E2B_07286169.

Organization: Health Canada

64 page(s)
January 2025

Req # A-2024-001153

Adverse Drug Reactions (ADRs). Report numbers: E2B_05862742, E2B_06186716, 1031530, E2B_05969683, E2B_05969586, E2B_06151402, E2B_06131046, E2B_06090780, E2B_06083598, E2B_03470780.

Organization: Health Canada

482 page(s)
January 2025

Req # A-2024-001159

Adverse Drug Reactions (ADRs). Report numbers: E2B_07451809, E2B_07489089.

Organization: Health Canada

23 page(s)
January 2025
Date modified: